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Introduction
FOX (Forkhead box) proteins, characterized by the possession
of a 100 amino acid winged helix DNA binding domain, are
chordate transcription factors that play important roles in the
regulation of growth and development (Kaestner et al., 2000;
Kaufmann and Knochel, 1996; Lehmann et al., 2003).
Hitherto, 17 subclasses (A-Q) of FOX proteins have been
defined based on phylogenetic analysis. FOXM1, in contrast to
most FOX factors that are tissue- or cell type-specific, is
expressed ubiquitously in all cells undergoing proliferation
(Korver et al., 1997; Yao et al., 1997; Ye et al., 1997). Loss of
FOXM1 function in knockout mice results in polyploidy,
suggesting that FOXM1 function is required for normal
coupling of DNA replication (at S phase) and chromosomal
segregation (at M phase) during cell cycle progression (Korver
et al., 1998).
FOXM1 expression peaks at G2/M and is believed to exert
its S-M coupling role by promoting M phase entry and
suppressing DNA re-replication (Korver et al., 1998; Leung et
al., 2001). Using doxycycline-inducible FOXM1-expressing
cell lines, we have previously demonstrated that
overexpression of FOXM1 stimulates cyclin B1 expression and
facilitates progression through the G2/M phase (Leung et al.,
2001). A similar growth stimulatory effect is also observed in
transgenic mice overexpressing FOXM1 in regenerating
hepatocytes (Ye et al., 1999). Furthermore, a liver-specific
deletion of the mouse Foxm1 gene clearly illustrates that
FOXM1 function is essential for progression into mitosis
(Wang et al., 2002).
Consistent with FOXM1 serving an M phase promoting
function, expression of cyclin B1 and Cdc25B is significantly
decreased in FOXM1 mutant mice (Wang et al., 2002). Cyclin
B1 and Cdc25B are important regulators of cyclin-dependent
kinase 1 (Cdk1) activity (Donzelli and Draetta, 2003; Doree
and Hunt, 2002). Cyclin B1 allosterically binds and activates
Cdk1 activity whereas Cdc25B, together with Cdc25C,
removes the inhibitory phosphorylations on Cdk1 imposed by
S-phase kinases Wee1 and Myt1. In transient reporter assays,
FOXM1 overexpression stimulates the activity of both the
cyclin B1 and Cdc25B promoters (Leung et al., 2001; Wang et
al., 2002; Wang et al., 2001).
FOXM1 requires activation by mitogenic signals to exert its
growth stimulatory effect. In transgenic mice overexpressing
FOXM1 in the liver, growth stimulation of hepatocytes is only
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regulatory effect via FOXM1c.
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evident upon partial hepatectomy when mitogenic signals are
generated (Ye et al., 1999). In contrast, significant growth
stimulation becomes detectable in cells overexpressing
FOXM1 only upon serum deprivation (Leung et al., 2001). It
has been proposed that requirement for FOXM1 function is not
limiting in the presence of serum when mitogenic factors are
abundant. Upon serum removal and subsequent decrease in
mitogenic signals, FOXM1 function within cells becomes
limiting and the cell cycle effect of FOXM1 overexpression
manifested. Further understanding of the G2/M regulatory
effect of FOXM1 requires identification of the signal
transduction cascades that modulate FOXM1 activity.
The mitogen-activated protein (MAP) kinase cascade is
activated by a variety of cellular stimuli to influence cell
growth and proliferation (Wilkinson and Millar, 2000). In
addition to its action on the G1/S phase, the Raf/MEK/MAPK
pathway has a G2/M regulatory effect (Pouyssegur et al., 2002;
Wilkinson and Millar, 2000). In synchronized NIH3T3
cells, ERK phosphorylation and hence activation of the
Raf/MEK/MAPK pathway persists throughout the cell cycle
(Roberts et al., 2002; Wright et al., 1999). When treated with
the specific MEK1 inhibitor PD098059 or U0126,
synchronized S-phase cells become arrested in the following
G2 phase with a concomitant decrease in cyclin B-Cdk1 kinase
activity (Roberts et al., 2002; Wright et al., 1999). Moreover,
ectopic expression of dominant-negative forms of MEK1
(MAPKK1) and ERK2 retards progression through G2/M,
suggesting that activation of the Raf/MEK/MAPK pathway is
required for G2/M transition (Roberts et al., 2002; Wright et
al., 1999). However, the molecular target(s) mediating this
G2/M regulatory effect remain elusive.
We hypothesize that FOXM1 is modulated by the
Raf/MEK/MAPK pathway and that it may mediate the G2/M
regulatory effect of Raf/MEK/MAPK signaling. In this study,
we use the human telomerase-immortalized cell line hTERT-
BJ1 to investigate the cell cycle-dependent regulation of
FOXM1. FOXM1 is found to be phosphorylated and
translocated to the nucleus before entry into the G2/M phase.
We present evidence that activity of the Raf/MEK/MAPK
pathway is both necessary and sufficient for the nuclear
translocation of FOXM1. Activation of the Raf/MEK/MAPK
pathway by overexpression of constitutively active MEK1 also
enhances the transactivating activity of FOXM1 on the cyclin
B1 promoter and this activating effect is shown to be mediated
through FOXM1c, the predominant isoform expressed in
multiple cell types and tissues. Activated Raf/MEK/MAPK
signaling promotes FOXM1 phosphorylation and mutations of
two ERK1/2 target sequences within FOXM1c abolish the
enhancing effect of Raf/MEK/MAPK signaling. Furthermore,
inhibition of Raf/MEK/MAPK signaling leads to decreased
expression of FOXM1 target genes, supporting the notion that
FOXM1 is an effector of Raf/MEK/MAPK signaling in G2/M
regulation. Our data provide important insights into the
regulation of cell cycle progression through G2/M by FOXM1
and the Raf/MEK/MAPK pathway.
Materials and Methods
Cell culture and cell cycle synchronization
Human neonatal foreskin fibroblasts hTERT-BJ1 (BJ1, BD
Biosciences) were cultured in Dulbecco’s modified Eagle’s
medium/medium 199 (4:1, v/v) and 10% (v/v) fetal bovine serum
(FBS), supplemented with 4 mM L-glutamine and 1 mM sodium
pyruvate. Mouse embryonic fibroblasts Swiss NIH 3T3 (American
Type Culture Collection) were cultured in DMEM and 10% FBS. BJ1
cells were synchronized by serum deprivation/aphidicolin double
block (Chen et al., 2001a). Briefly, ~1.5×105 cells were seeded in 100
mm plates. After 36 hours, cells were washed three times with PBS
and replenished with DMEM/M199 and 0.1% FBS for 48 hours.
Afterwards, cells were treated with DMEM/M199 and 10% FBS
containing 1 µM aphidicolin for 20 hours. To release cells from arrest
at the G1/S boundary, they were washed once with PBS and
replenished with DMEM/M199 and 10% FBS. Subconfluent NIH 3T3
cells were synchronized at G1/S and G2 phases by incubation with
200 µM L-mimosine and 500 ng/ml etoposide, respectively, for 48
hours.
Flow cytometry
Cells in 100 mm plates were trypsinized and resuspended in
DMEM/M199 and 10% FBS. Cells were resuspended in 70% (v/v)
ethanol for storage at –20°C before measurement. Prior to
measurement, cells were resuspended in 1 ml serum-free medium and
incubated with 16 µg/ml RNase I for 3 minutes at room temperature.
After RNA removal, cells were incubated with 250 µl propidium
iodide (PI) solution (250 µg/ml PI in PBS with 10% Triton™ X-100)
for 15 minutes at 4°C in the dark. Cells were then passed through an
EPICS Elite ESP high performance cell sorter (Coulter Electronics),
equipped with a red pass filter of 600 nm wavelength. Raw data were
analyzed with EXPO™ for Windows 2.0 and Modfit™ LT version 2.0
(Verity software) to eliminate aggregated cells for determination of
cell cycle distribution.
Western blotting
Cells were lysed with 10 mM Tris-HCl (pH 7.4) containing 1% SDS,
1 mM EGTA, 1 mM DTT and phosphatase inhibitors (0.1 mM sodium
orthovanadate, 50 mM β-glycerophosphate). Phosphatase treatment of
cell lysate was performed by incubation with 10 U calf intestinal
phosphatase (New England Biolabs) at 37°C for 1 hour. Protein
samples were separated by SDS-PAGE in 8% Laemmli gels and
electroblotted onto Hybond C Super nitrocellulose membranes
(Amersham Life Sciences). Blots were incubated with anti-FOXM1
antiserum (1:200, MPP2-C20 from Santa Cruz), anti-β-Tubulin
antiserum (1:500, DM1B from Neomarker), anti-phosphoserine
antiserum (1:250, Zymed), anti-ERK antiserum (1:200, C-14 from
Santa Cruz), anti-phosphoERK antiserum [1:1000, p44/42 MAP
Kinase (Thr202/Tyr204) from Cell Signaling Technology], anti-cyclin
B1 antiserum (1:200, GNS1 from Santa Cruz) or anti-Cdc25B
antiserum (1:200, H-85 from Santa Cruz). Antigen-antibody
complexes were detected using secondary antibodies conjugated to
horseradish peroxidase (1:2000, anti-rabbit or anti-mouse IgG
purchased from BD Biosciences) and visualized using the
SuperSignal ECL detection system (Pierce). Blots for reprobing were
stripped in 0.1 M glycine buffer (pH 2.9).
Immunostaining and confocal microscopy
To study FOXM1 subcellular localization by immunostaining, 2-
5×104 BJ1 cells were seeded on coverslips placed in 35 mm dishes.
Cells were synchronized and harvested at different time intervals by
fixing with methanol/acetone (1:1, v/v). Fixed cells were treated with
anti-FOXM1 antibody (1:200, MPP2-C20 from Santa Cruz) and then
the fluorochrome-tagged secondary antibody (1:200, Alexa fluor 488-
conjugated goat anti-rabbit IgG from Molecular Probes). Following
incubation in PBS with 12.5 µg/ml propidium iodide and 0.5% Triton
X-100, coverslips were mounted on slides with Vectashield™ (Vector
Lab, Burlingame). To investigate whether U0126 could block FOXM1
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nuclear translocation, synchronized cells were treated with 10 µM
U0126 (or U0124) for 1 hour at 7 hours after aphidicolin removal.
Cells were harvested at 8 hours after release for immunostaining. To
study the effect of activation of Raf/MEK/MAPK signaling on
FOXM1 localization, asynchronized BJ1 cells were incubated with
200 µM aurintricarboxylic acid (ATA) for 1 hour before their harvest
for immunostaining. As controls, asynchronized cells were incubated
with DMSO instead of ATA, or pretreated with 10 µM U0126 (or
U0124) for 1 hour before incubation with ATA.
Immunoprecipitation
FOXM1 was immunoprecipitated from BJ1 cells using the following
procedure. Anti-FOXM1 antibody (4 µg/reaction, MPP2-K19 from
Santa Cruz) was allowed to bind to protein A/G plus agarose (20
µg/reaction, Santa Cruz) by rotating overnight in 100 µl PBS at 4°C.
Antibody-bound agarose beads were washed twice with RIPA buffer
(PBS, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, pH 7.2) and
then once with PBS. BJ1 cells at 80-90% confluency were treated with
200 µM ATA or 200nM TPA for 1 hour before harvest and lysis in
RIPA buffer containing protease (Complete™ protease inhibitor
cocktail, Roche) and phosphatase inhibitors. Cell lysates were
subjected to one freeze-thaw cycle, passed through 21-gauge needles,
briefly sonicated and then pre-cleared with 0.4 µg normal rabbit serum
and 20 µg protein A/G plus agarose for 30 minutes at 4°C. Afterwards,
lysates were transferred to tubes containing the antibody-bound
beads and rotated for 4.5 hours at 4°C. Beads were then washed four
times with RIPA buffer containing protease inhibitors and once
with PBS containing protease inhibitors. Immunoprecipitates were
resuspended in 50 µl sample loading buffer, resolved by SDS-PAGE
and immunoblotted with anti-FOXM1 (MPP2-C20) and anti-
phosphoserine antibodies.
Chromatin immunoprecipitation (ChIP) assays were performed
using the ChIP kit from Upstate Biotech with the following
modifications. Phosphatase inhibitors were added to the SDS lysis and
ChIP dilution buffers. BJ1 cells were lysed in 200 µl PIPES buffer [5
mM (pH 8.0), 85 mM KCl, 0.5% NP-40] containing protease
inhibitors for 10 minutes at 4°C. After resuspension in SDS lysis
buffer, 2.5 µg anti-FOXM1 (MPP2-K19) or anti-actin antibody was
added. Cyclin B1 promoter sequence was amplified using AccuPrime
SuperMix II PCR kit (Invitrogen) and two primers (5′-CCTCC-
AACCCAGAGAGTTGTTGC-3′ and 5′-AGCCAAGGACCTACAC-
CCAGCA-3′) for 35 cycles. PCR products were visualized by staining
with SYBR Green I (1:10,000, Molecular Probes). As a positive
control, 1/20 of the sonicated cell lysate was also PCR-amplified. Data
were quantified using a Biorad imaging system and TotalLab™
software (Nonlinear Dynamics).
Transient reporter assays
The transactivating effect of FOXM1 on cyclin B1 promoter activity
was assayed as previously described (Leung et al., 2001). Plasmids
were transfected into NIH3T3 cells seeded in 24-well plates using
Fugene 6 as transfection reagent (Roche). For a typical transfection,
100 ng cyclin B1 reporter (pGL3-CycBpro), 0.4 ng control reporter
(pRL-SV40) and 100 ng expression plasmids were mixed with 0.6 µg
Fugene 6. The expression vectors pSRα-HA-MAPKK-SDSE
(caMEK1) and pSRα-HA-MAPKK-SASA (dnMEK1) were kindly
provided by E. Nishida (Fukuda et al., 1997). pcDNA3-FOXM1b was
generated by deletion of exon Va from pcDNA3-FOXM1c using
QuikChangeTM site-directed mutagenesis kit (Stratagene) and two
primers, 5′-GACATTGGACCAGGTGTTTAAGCAGCAGAAACG-
ACCGAATCCAG-3′ and 5′-CTGGATTCGGTCGTTTCTGCTG-
CTTAAACACCTGGTCCAATGTC-3′. To generate pcDNA3-
FOXM1c∆Cter, coding sequence excluding the carboxyl 71 amino
acids of FOXM1c was PCR-amplified using pcDNA3-FOXM1c as
template and the primers 5′-GTTGTTGGTACCGAATTCCACCAT
GGACTACAAGGACGACGATGACAAGAAAGCTAGCCCCCGTC-
GG-3′ and 5′-GTTGTTCTCGAGCTAGGGGACGTCTATATCTGA-
GGG-3′. The resulting fragment was inserted into pcDNA3 using
EcoRI and XhoI sites. Ser331 and Ser704 within the ERK1/2 target
sequences were singly or doubly mutated to alanine in pcDNA3-
FOXM1c using the QuikChangeTM site-directed mutagenesis kit
(Stratagene). pcDNA3 and pSRα were added to normalize the amount
of vectors across all transfections. All experiments were conducted in
triplicate using independent cultures and the results shown are the
mean±s.e.m.
RNA extraction and RT-PCR
RNA from cells and tissues were extracted using the TRIzol™ reagent
(GibcoBRL) according to the manufacturer’s instruction. Tissue
samples (10-20 ng) were homogenized with a Dounce homogenizer
followed by brief sonication at 4°C. For expression analysis of
FOXM1 isoforms, cDNAs were synthesized using 2 µg total RNAs,
SuperScript™ RT-PCR system (Invitrogen) and oligo(dT)20 as the
primer. cDNAs were subjected to PCR amplification using Platinum®
Taq DNA polymerase kit (Invitrogen). FOXM1b and FOXM1c
cDNAs (human), and Marathon-ready™ testis cDNA libraries
(human and mouse, Clontech), were also PCR-amplified as controls.
FOXM1 and GAPDH cDNAs were amplified using the following
primers and cycle numbers: mouse FOXM1, 5′-ACCCAAGTGCCA-
ATCGCCACTTG-3′ and 5′-GAAGCGGGGCTATTCCTTCACTGG-
3′, 28 cycles; human FOXM1, 5′-CACCCCAGTGCCAACCGCTA-
CTTG-3′ and 5′-AAAGAGGAGCTATCCCCTCCTCAG-3′, 32
cycles; mouse GAPDH, 5′-GCAGGGGGAGCCAAAAGGG-3′ and
5′-TGCCAGCCCCAGCGTCAAAG-3′, 30 cycles. For semi-
quantitative RT-PCR analysis to determine the effect of
Raf/MEK/MAPK inhibition on cyclin B1 expression, synchronized
hTERT-BJ1 cells were treated with 25 µM U0126 at 5.5 hours after
aphidicolin removal. Total RNAs were extracted at different time
intervals and 0.5 µg of each sample was subjected to reverse
transcription using random hexamers to prime cDNA synthesis.
cDNA amounts and cycle numbers were optimized to ensure that
amplification was within the linear range for quantitative analysis.
Cyclin B1 and GAPDH cDNAs were amplified using 25 and 24
cycles, respectively. PCR fragments were resolved in 1% (w/v)
agarose gels and detected with SYBR Green I.
Results
FOXM1 is phosphorylated and translocated to the
nucleus just before entry into the G2/M phase
FOXM1 expression is initiated before entry into S phase and
its level persists during the S phase (Korver et al., 1998; Leung
et al., 2001). However, dramatic transcriptional stimulation of
the FOXM1 target gene cyclin B1 does not occur until the
G2/M phase (Hwang et al., 1995; Hwang et al., 1998). This
time lag could be due to a post-translational regulation of
FOXM1 function and it has been previously reported that
FOXM1 exhibits nuclear translocation in hepatocytes
stimulated to proliferate (Ye et al., 1999), but it remains unclear
how this nucleocytoplasmic shuttling of FOXM1 is regulated.
As a first objective, we sought to investigate whether there is
regulation of post-translational modification and nuclear
translocation of FOXM1 in a cell cycle-dependent manner.
The human foreskin fibroblastic cell line hTERT-BJ1 (BJ1),
which possesses a functional G1/S checkpoint for efficient
synchronization at the G1/S boundary, was used for this
analysis. BJ1 cells, synchronized using serum starvation/
aphidicolin double block, were harvested for flow cytometric
and immunoblot analyses at various time intervals after release
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from cell cycle arrest. DNA analysis indicated that
synchronized BJ1 cells gradually progressed through the cell
cycle (Fig. 1A). More than 40% of cells entered G2/M phase
at 9 hours after release and many cells re-entered the G1 phase
of the next cycle at 12 hours. From 0.5 to 6 hours after release,
western analysis revealed low levels of FOXM1 expression in
late-G1 and S cells. FOXM1 level increased at 9 hours after
release, when cells entered into the G2/M phase, and there was
a concomitant mobility shift of the FOXM1 band (Fig. 1B,
arrowhead). At 12 hours after release, a discrete FOXM1 band
was discernible and a faint band of even slower mobility
appeared. FOXM1 was previously shown to be phosphorylated
at M phase (Korver et al., 1997; Westendorf et al., 1994). To
test whether the early mobility shift at 9 hours after release also
corresponded to phosphorylation of FOXM1, the cell lysate
was treated with calf intestine phosphatase (CIP). This
treatment abolished the FOXM1 mobility shift, suggesting that
phosphorylation was the post-translational modification
involved (Fig. 1C).
To determine whether FOXM1 phosphorylation was
associated with any change in subcellular localization, BJ1 cells
seeded on coverslips were similarly synchronized and harvested
for immunostaining. Cells were immunostained with anti-
FOXM1 antibody and counterstained with propidium iodide to
label the nuclear DNA. Before removal of aphidicolin (0 hour),
low levels of FOXM1 were detected in the cytoplasm (Fig. 1D
a-c, arrow). At 3 hours and 6 hours after release, when most
cells were in S phase, FOXM1 immunoreactivity was still
predominately cytoplasmic (Fig. 1D d-i, arrows). Interestingly,
there was a dramatic increase in nuclear-expressing cells at 9
hours after release, when cells at late S phase entered into the
G2/M phase; FOXM1 remained nuclear-localized at 12 hours
after release (Fig. 1D j-o, arrowheads). These findings suggest
a tight regulation of FOXM1 subcellular localization. FOXM1
is mainly cytoplasmic in late-G1 and S phases. Late in S phase,
FOXM1 becomes phosphorylated and there is an accompanying
shuttling of the protein to the nucleus. These findings support
the idea that FOXM1 plays a functional role at the G2/M phase
when it activates expression of target genes like cyclin B1.
FOXM1 nuclear translocation requires Raf/MEK/MAPK
signaling
Previous studies have shown that activation of the
Raf/MEK/MAPK pathway is required for progression through
the G2/M phase (Roberts et al., 2002; Wright et al., 1999) but
little is known about the molecular mechanism underlying this
G2/M regulatory effect. As FOXM1 exerts a modulatory effect
on cell cycle progression through G2/M and its function requires
activation by mitogenic signals (Leung et al., 2001; Ye et al.,
1999), we speculate that FOXM1 may be one of the molecular
targets of the Raf/MEK/MAPK pathway. To perturb activity of
the Raf/MEK/MAPK pathway, we used the MEK1/2 inhibitor
U0126 and aurintricarboxylic acid (ATA), an activator acting
upstream of MEK1/2 in the Raf/MEK/MAPK pathway (Beery et
al., 2001). Immunoblot analysis of ERK and phosphoERK
expression indicated that U0126 at 10 µM completely suppressed
Raf/MEK/MAPK signaling (Fig. 2A). Pathway activity was
stimulated by ATA at 200 µM but this could be counteracted by
pre-treatment with increasing concentrations of U0126.
To address whether the subcellular localization of FOXM1 is
modulated by Raf/MEK/MAPK signaling, synchronized BJ1
cells were treated with U0126 (10 µM) at 7 hours after release,
one hour before their harvest for immunostaining (Fig. 2B).
Consistent with the results shown in Fig. 1, FOXM1 in cells
without U0126 treatment entered the nucleus at 8 hours after
release (Fig. 2C,D). This nuclear entry was abrogated in the
presence of U0126 (Fig. 2E). U0124, an inactive analog of
U0126, did not have any inhibitory effect on FOXM1 nuclear
translocation (Fig. 2F). These results suggest that inhibition of
the Raf/MEK/MAPK pathway prevents nuclear translocation of
FOXM1.
If activity of the Raf/MEK/MAPK pathway is required for
the nuclear translocation of FOXM1, we would expect an
enhancement of FOXM1 nuclear import upon ATA treatment
(Fig. 2G). Without synchronization and drug treatment, most
BJ1 cells were at G1 or S phase with FOXM1 expressed in the
cytoplasm (Fig. 2H). As expected, incubation of asynchronized
BJ1 cells with ATA (200 µM) for 1 hour increased dramatically
the number of nuclear-stained cells (Fig. 2I), suggesting that
ATA promoted nuclear translocation of FOXM1. To confirm
that this ATA-induced nuclear translocation was mediated by
Raf/MEK/MAPK signaling, we pre-treated BJ1 cells with
U0126 or U0124 for 1 hour before ATA addition. ATA-induced
nuclear translocation was abolished in the U0126-treated but
not the U0124-treated cells (Fig. 2J,K). Taken together, we
demonstrate that activation of the Raf/MEK/MAPK pathway
is sufficient to induce the nuclear translocation of FOXM1.
Constitutively active MEK1 enhances the transactivating
activity of FOXM1c, but not FOXM1b
FOXM1 has previously been shown to activate the cyclin B1
promoter in doxycycline-inducible cell lines and transient
reporter assays (Leung et al., 2001; Wang et al., 2001). In this
study, we could immunoprecipitate the cyclin B1 promoter
sequence using an anti-FOXM1 antibody in a chromatin
immunoprecipitation (ChIP) assay, suggesting that FOXM1 is
a direct regulator of cyclin B1 transcription (Fig. 3A). To test
whether the enhanced nuclear translocation of FOXM1 upon
stimulation of Raf/MEK/MAPK signaling has any effect on the
transactivating activity of FOXM1, a constitutively active form
of MEK1 (caMEK1) (Fukuda et al., 1997) was coexpressed
with FOXM1 and the cyclin B1 reporter in transient assays.
Three isoforms of FOXM1, FOXM1a, FOXM1b and FOXM1c,
have previously been reported (Kaestner et al., 2000) but only
FOXM1b and FOXM1c exhibit transactivating activity in
reporter assays (Leung et al., 2001; Ye et al., 1997). We have
been doubtful about the physiological significance of FOXM1a,
as this isoform is not conserved in mouse (Fig. S1 in
supplementary material). Therefore, only the b and c isoforms
(Fig. 3B) were individually tested in our assays. Similar to
previous findings (Leung et al., 2001; Ye et al., 1997), FOXM1b
and FOXM1c (60 ng) showed similar transactivating activity
when tested in NIH 3T3 cells (Fig. 3C). However, only
FOXM1c, but not FOXM1b, displayed significant enhancement
of transactivating activity when caMEK1 (30 ng) was
coexpressed (Fig. 3D). FOXM1c activity was enhanced 6.8-fold
when amount of FOXM1 was increased from 0 to 60 ng.
Next, we tested whether both functional FOXM1c and
MEK1 are required for the transcriptional enhancing effect.
caMEK1 and FOXM1c, when individually tested, exhibited
Journal of Cell Science 118 (4)
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Fig. 1. FOXM1 is phosphorylated and translocated to the nucleus before entry into the G2/M phase. (A) Flow diagrams of asynchronized and
synchronized BJ1 cells. BJ1 cells were synchronized at the G1/S boundary by serum starvation/aphidicolin double block. Cells were released
from arrest by removal of aphidicolin. At different time intervals after release, cells were harvested and stained with propidium iodide for DNA
analysis using a flow cytometer. Synchronized cells gradually progressed through the cell cycle and G2/M cells could be detected at both 9
hours and 12 hours after release. (B) Cells at different time intervals after aphidicolin release were harvested for immunoblot analysis using
anti-FOXM1 and anti-tubulin antibodies. Progressive mobility shifts (denoted by arrowheads) of the FOXM1 band were observed at 9 hours
and 12 hours after release. (C) The cell lysate at 9 hours after release was treated with calf intestine phosphatase (for 1 hour) before
immunoblot analysis. Such treatment abolished the mobility up-shift of the FOXM1 band. (D) BJ1 cells grown on coverslips were
synchronized by serum starvation/aphidicolin double block and fixed at various time points after removal of aphidicolin. Cells were
immunostained with anti-FOXM1 antibody and counterstained with propidium iodide to detect nuclear DNA. Merged images of FOXM1 and
nuclear staining are also shown. FOXM1 was predominantly cytoplasmic (arrows) at 0 hour, 3 hours and 6 hours after release; FOXM1 became
mainly nuclear (arrowheads) at 9 hours and 12 hours after release.
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only a twofold stimulatory effect owing to the presence of
endogenous FOXM1 and MEK1 activity (Fig. 3E). The effect
was increased to 15.5-fold when caMEK1 and FOXM1 were
coexpressed. To verify that FOXM1 is downstream of MEK1
to mediate the activating effect, a FOXM1 mutant missing the
carboxyl 71 amino acids (FOXM1∆Cter; Fig. 3B) was tested.
Based on previous structure-function analysis, this deleted
region is within the transactivation domain and the mutant
protein synthesized is transcriptionally inactive (R.Y.M.M. and
K.-M.Y., unpublished). FOXM1∆Cter, when coexpressed with
caMEK1, displayed a mildly suppressive effect (Fig. 3E). The
enhancing effect was also lost when a dominant negative form
of MEK1 (dnMEK1) (Fukuda et al., 1997) was coexpressed.
In transiently transfected cells, overexpression of caMEK1 and
dnMEK1 did show the expected effects on Raf/MEK/MAPK
activity, monitored by immunoblot analysis of phosphoERK
expression (Fig. 3F). These data strongly support the fact that
caMEK1 enhancement of FOXM1 activity requires the
presence of functional FOXM1 protein.
FOXM1c is the major isoform expressed in cells and
tissues
The responsiveness of FOXM1 to Raf/MEK/MAPK stimulation
in BJ1 cells points to FOXM1c being the predominantly
expressed isoform. To test this notion, we subjected total RNA
isolated from BJ1 cells to RT-PCR analysis using primers that
flank the coding sequence of exon Va, which is missing in the
FOXM1b isoform (Fig. 4A). The primers should generate PCR
products of 323 bp and 368 bp if FOXM1b and FOXM1c
transcripts, respectively, are expressed. As the testis has
previously been found to express both transcripts (Yao et al.,
1997), testis cDNA libraries were similarly amplified to generate
the FOXM1b- and FOXM1c-specific fragments as size controls.
In BJ1 cells synchronized at different cell cycle phases, only the
FOXM1c fragment was detectable (Fig. 4B), supporting a
predominant expression of FOXM1c. The NIH3T3 cell line used
as host in our transient reporter assays, and a few neonate and
adult tissues that are rich in mitotically active progenitor-like
cells and hence FOXM1 expression, were also analyzed. Again,
NIH3T3 cells, synchronized or not, and the various tissues
mainly showed amplification of the FOXM1c fragment (Fig.
4C,D).
Identification of ERK1/2 target sites within FOXM1c and
their requirement for caMEK1 enhancement
ERK1 and ERK2 are the effector serine/threonine kinases
Journal of Cell Science 118 (4)
Fig. 2. Activity of the Raf/MEK/MAPK pathway is required for nuclear translocation of FOXM1. (A) Immunoblot analysis of total ERK and
phosphoERK expression to monitor the effect of U0126 and ATA treatment on Raf/MEK/MAPK activity. (B) Scheme for drug treatment to
inhibit MEK1/2. Synchronized BJ1 cells were incubated with U0126 (10 µM) or the inactive analog U0124 (10 µM) from 7 hours to 8 hours
after aphidicolin release. Cells were harvested 1 hour later (i.e. at 8 hours after release) and immunostained for FOXM1. (C) Without drug
treatment, FOXM1 was predominantly cytoplasmic at 7 hours after release. (D) 1 hour later, FOXM1 became mainly nuclear. (E) Treatment
with U0126 abolished FOXM1 nuclear translocation at 8 hours after release. (F) FOXM1 nuclear translocation was not affected by U0124
treatment. (G-K) ATA promotes nuclear translocation of FOXM1. (G) Scheme for ATA treatment and U0126/U0124 pre-treatment. (H) In cells
treated with solvent (DMSO), FOXM1 was predominantly expressed in the cytoplasm. (I) After incubation with 200 µM ATA for 1 hour,
FOXM1 became localized mainly to the nucleus. (J) ATA stimulation of FOXM1 nuclear translocation was abrogated by pre-incubation with 10
µM U0126 for 1 hour. (K) U0124 pre-treatment could not counteract the stimulatory effect of ATA.Jo
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believed to mediate the regulatory effect of the Raf/MEK/MAPK
pathway by directly phosphorylating target proteins (Wilkinson
and Millar, 2000). They recognize Pro-X-Ser/Thr-Pro (where X
represents any amino acid) as the substrate consensus sequence
(Thomas, 1992). Analysis of the FOXM1c coding sequence
identifies three motifs (PGS331P, PRT620P and PGS704P; Fig.
5A) that resemble the ERK1/2 target sequence. Of particular
interest are the 331 and 704 motifs, which are conserved among
the human, rat and mouse FOXM1 sequences (Fig. 5B).
Aurintricarboxylic acid (ATA) and TPA, which are activators
of IGF-1 receptor and protein kinase C signaling, respectively,
have been previously used to stimulate the Raf/MEK/MAPK
pathway (Beery et al., 2001; Chen et al., 2001b). To provide
more evidence that FOXM1 is a direct target of
Raf/MEK/MAPK signaling, we tested whether ATA and TPA
are able to induce phosphorylation of FOXM1. FOXM1 was
immunoprecipitated from activator-treated and non-treated BJ1
cells using anti-FOXM1 antibody. The immunoprecipitates were
subjected to immunoblot analysis using both anti-FOXM1 and
anti-phosphoserine antibodies (Fig. 5C). Treatment with ATA
and to a lesser extent TPA, enhanced the intensity of the
phosphorylated FOXM1 (up-shifted) band. Notably, anti-
phosphoserine antibody mainly detected the upper band of the
FOXM1 doublet, indicating that FOXM1 was highly
phosphorylated at serines with ATA treatment. Phosphorylation
was weaker with the TPA-stimulated or non-treated sample.
Fig. 3. Constitutively active
MEK1 enhances the
transactivating activity of
FOXM1c. (A) Chromatin
immunoprecipitation assays
of asynchronized BJ1 cells
were carried out as
described in Methods
section to detect FOXM1
binding to the cyclin B1
promoter. Cyclin B1 DNA
was enriched more than 50-
fold by the anti-FOXM1
antiserum. (B) Schematic
diagrams of FOXM1c,
FOXM1b and
FOXM1c∆Cter. Positions of
the DNA binding domain
(DBD), exon Va and
transactivation domain
(TAD) are shown. FOXM1b
lacks exon Va.
FOXM1c∆Cter was
generated by deletion of the
last 71 amino acids of
FOXM1. (C-E) Transient
reporter assays. NIH3T3
cells were co-transfected
with the various expression
plasmids and cyclin B1
luciferase reporter. 48 hours
after transfection, cells were
harvested for luciferase
assay. (C) 60 ng of
FOXM1c, FOXM1b or the
control vector pcDNA3 was
co-transfected with the
cyclin B1 reporter. Both
FOXM1c and FOXM1b
showed ~2.5-fold
stimulation of the cyclin B1
promoter when compared
with the vector control.
(D) caMEK1 enhances the
transactivating activity of
FOXM1c. Co-transfection
of caMEK1 (30 ng) with an increasing amount of FOXM1 strongly enhanced the transactivating activity of FOXM1c, but not FOXM1b.
(E) The caMEK1 enhancing effect requires the presence of functional FOXM1 protein. Various amounts of FOXM1 and MEK1 expression
plasmids, and empty vectors (pcDNA3 and pSRα), were co-transfected as indicated. Both caMEK1 and functional FOXM1c are required for
the synergistic activation of cyclin B1 promoter. (F) Western blot to demonstrate the activating and inhibitory effect of caMEK1 and dnMEK1,
respectively, on Raf/MEK/MAPK signaling.
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To test directly the regulatory importance of the 331 and 704
motifs, serine residues of these motifs were singly or doubly
substituted with the unphosphorylatable amino acid alanine and
the mutant constructs assessed for caMEK1 activation using the
cyclin B1 reporter in transient assays (Fig. 5D). Mutation of the
331 motif led to a 48% suppression of caMEK1 enhancement.
A 60% loss of caMEK1 enhancement was detected when the
704 motif was similarly mutated. caMEK1 enhancement was
totally lost when both motifs were substituted in the SASA
double mutant. All the mutant constructs were HA-tagged and
western analysis confirmed expression of the different mutant
FOXM1 proteins (Fig. 5D). These results demonstrate that both
the 331 and 704 motifs are required for mediating the enhancing
effect of the Raf/MEK/MAPK pathway.
Inhibition of the Raf/MEK/MAPK pathway slows down
transition at G2/M and reduces expression of FOXM1
target genes
The data presented above are supportive of our hypothesis that
Raf/MEK/MAPK signaling promotes cell cycle progression
through G2/M via activation of FOXM1 function. If FOXM1 is
indeed a G2/M effector of the Raf/MEK/MAPK pathway, we
would expect G2/M delay and suppression of FOXM1 target
gene expression upon inhibition of the Raf/MEK/MAPK
pathway. To test this argument, we inhibited Raf/MEK/MAPK
signaling in BJ1 cells at S and G2/M phases and followed the
effect on cell cycle progression and gene expression. BJ1 cells
were again synchronized at the G1/S boundary by serum
deprivation/aphidicolin double block. Cells were allowed to re-
enter S phase following the removal of aphidicolin. The MEK1
inhibitor U0126 was added at 5.5 hours after release to inhibit
the Raf/MEK/MAPK pathway. Afterwards, cells were harvested
at various time points for expression and DNA analyses. Rate of
progression through G2/M was deduced based on the kinetics of
re-entry into the subsequent G1 phase.
Western blots of total ERK revealed that ERK levels were
rather constant throughout the cell cycle (Fig. 6C). Without drug
treatment, ERK was highly phosphorylated from 1.5 hours to 10
hours after release, suggesting activation of the Raf/MEK/
MAPK pathway. When U0126 was added at 5.5 hours,
phosphorylation of ERK was abolished henceforth. Both non-
treated and U0126-treated BJ1 cells progressed into the G2/M
phase and a G2/M peak became discernible at 9 hours after
release (Fig. 6A). Without drug treatment, the percentage of G1
cells increased at 11 hours after release and thereafter, indicating
G1 re-entry of cells previously in the G2/M phase (Fig. 6A). In
contrast, G1 re-entry of U0126-treated cells was delayed, as
indicated by the lower percentage of G1 cells at 12.5-15.5 hours
after release. Therefore, inhibition of Raf/MEK/MAPK
signaling slows down cell cycle progression through G2/M.
Cyclin B1 is a direct transcriptional target of FOXM1. To
investigate the effect of U0126 treatment on cyclin B1
expression, RNA isolated from the samples at different time
points were subjected to semi-quantitative RT-PCR analysis.
GAPDH levels were also analyzed in parallel as loading
controls. Cyclin B1 levels were found to increase 8 hours after
release, just before cells entered the G2/M phase (Fig. 6B).
This increase was greatly attenuated with U0126 treatment,
suggesting an inhibition of FOXM1 function. The inhibitory
effect of U0126 on the expression of cyclin B1 and another
putative FOXM1 target Cdc25B was also analyzed by
immunoblotting (Fig. 6C). In control cells, the protein levels of
cyclin B1 increased at around 9 hours after release and peaked
at 11 hours. In U0126-treated cells, the increase was strongly
suppressed and cyclin B1 levels became barely detectable
Journal of Cell Science 118 (4)
Fig. 4. FOXM1c is the predominant isoform expressed in BJ1, NIH 3T3 and various mouse tissues. (A) RT-PCR assays were designed using
human and mouse primers, which flank exon Va, to assess the expression of FOXM1b and FOXM1c transcripts. FOXM1b and FOXM1c
transcripts generate PCR fragments of 323 and 368 base pairs, respectively. (B-D) RT-PCR analysis. As positive controls, cDNAs encoding human
FOXM1b and FOXM1c, and human and mouse testis cDNA libraries, were PCR-amplified to generate the FOXM1b and FOXM1c bands.
GAPDH transcripts were also PCR-amplified in the mouse tissue samples to control for possible loading differences. mRNA of asynchronized and
synchronized BJ1 cells [0 hour (G1), 4.5 hours (S), 9 hours (G2) after aphidicolin release] (B) and asynchronized, L-mimosine-arrested (G1/S) and
etoposide-arrested (G2) NIH 3T3 cells (C) were extracted for RT-PCR analysis. Intestine (I), heart (H), liver (Li) and lung (Lu) of day 1 neonates,
and pancreas (P) and thymus (Th) of adult mice, were harvested for RT-PCR analysis and compared to that of testis (Te) cDNA library (D). 
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between 11 and 14 hours after release. A milder inhibitory effect
was also observed for Cdc25B expression. Thus, inhibition of
Raf/MEK/MAPK signaling leads to suppression of G2/M
transition and FOXM1 function, consistent with the idea that
Raf/MEK/MAPK signaling mediates its G2/M effect via
regulation of FOXM1 function.
Discussion
The loss of S-M coupling in mice deficient in FOXM1 function
first implicates FOXM1 as a critical regulator of cell
proliferation (Korver et al., 1998). The polyploidy phenotype
suggests a requirement of FOXM1 function for entry into
mitosis. This M-phase-promoting function of FOXM1 is
corroborated by a recent demonstration (Wang et al., 2002) that
FOXM1 function is essential for hepatocytes to enter into
mitosis. One salient feature of the M-phase-promoting function
of FOXM1 is its dependency on mitogenic stimulation (Leung
et al., 2001; Ye et al., 1999). Our demonstration that
Raf/MEK/MAPK signaling stimulates FOXM1 nuclear
translocation and transactivating activity offers an explanation to
this mitogenic dependency, and provides an important insight
into how the Raf/MEK/MAPK pathway modulates cell cycle
progression through the G2/M phase.
Using synchronized BJ1 cells, we show that FOXM1 is
phosphorylated just before G2 entry and there is an associated
nuclear translocation of FOXM1. The phosphorylation of
FOXM1 observed in this study appears earlier than the M-phase
phosphorylation of FOXM1 detected in Rat-1 cells (Korver et
al., 1997). Increased up-shifts of the FOXM1 band from 9 to 12
Fig. 5. Identification and functional analysis of
the ERK1/2 target sites within FOXM1c.
(A) Sequence analysis of FOXM1c identifies
three putative ERK1/2 phosphorylation sites
(PXS/TP) at amino acids 329-332, 618-621 and
702-705. DBD, DNA binding domain; TAD,
transactivating domain. (B) The 331 and 704
motifs are conserved in the FOXM1c coding
sequences from multiple species. (C) Activated
Raf/MEK/MAPK signaling stimulates FOXM1
phosphorylation. Asynchronized BJ1 cells were
incubated with 200 µM ATA or 200 nM TPA for
1 hour. Cells with or without drug treatment were
lysed and endogenous FOXM1
immunoprecipitated with anti-FOXM1 antibody
or control rabbit antiserum. The
immunoprecipitates were immunoblotted with
anti-FOXM1 and anti-phosphoserine antibodies.
ATA and to a lesser extent TPA, enhanced the
phosphorylation of FOXM1. Note that anti-
phosphoserine antibody selectively detected the
upper band of the FOXM1 doublet. (D) Both the
331 and 704 motifs are important for mediating
the caMEK1 enhancing effect. The wild type (WT) and various substitutive mutants (S331A, S704A, SASA) were co-transfected with caMEK1
in transient reporter assays as described in Fig. 3. caMEK1 enhancement is shown as percentage of activation compared to the wild-type control
(100%). Immunoblot analysis revealed expression of the various HA-tagged, mutant FOXM1c proteins.
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hours after release (Fig. 1B) are suggestive of
multiple FOXM1 phosphorylations catalyzed by
multiple kinases. Our findings are consistent
with phosphorylation of FOXM1 by the
Raf/MEK/MAPK pathway at late-S phase, later
followed by FOXM1 phosphorylation by
activated Cdk1 at M phase.
Activity of the Raf/MEK/MAPK pathway is
both necessary and sufficient for stimulating
nuclear translocation of FOXM1. FOXM1
nuclear entry is abolished by incubation with the
MEK1/2 inhibitor U0126 at S phase. Activating
the Raf/MEK/MAPK pathway with ATA
stimulates FOXM1 nuclear entry. This activating
effect is abrogated by U0126, affirming that the
effect is mediated via MEK1/2. The stimulatory
effect on FOXM1 by the Raf/MEK/MAPK
pathway is an interesting contrast to the
inhibitory effect on FOXOs by the PI3K-PKB
pathway (Burgering and Kops, 2002; Van Der
Heide et al., 2004). The PI3K-PKB pathway
exerts a negative effect on FOXO activity via
PKB-mediated phosphorylation and nuclear
export of FOXO proteins. It is worth noting that
similar treatment of BJ1 cells with the PI3K
inhibitors Wortmannin and LY294002 did not
have any significant effect on FOXM1
subcellular localization (R.Y.M.M. and K.-M.Y.,
unpublished). Both FOXM1 and FOXO factors
have previously been reported to regulate cyclin
B1 expression (Alvarez et al., 2001; Leung et al.,
2001). The different FOX factors may be
integrating signals from multiple signaling
pathways to effect changes in cell cycle
progression.
Besides nuclear translocation, activation of the
Raf/MEK/MAPK pathway strongly enhances the
ability of FOXM1 to transactivate cyclin B1
promoter in transient reporter assays. ChIP
assays affirm binding of cyclin B1 promoter by
Journal of Cell Science 118 (4)
Fig. 6. Inhibition of Raf/MEK/MAPK signaling
leads to G2/M delay and downregulation of FOXM1
target genes. U0126 (25 µM) was added to
synchronized BJ1 cells at 5.5 hours after aphidicolin
release (black arrows). Cells were harvested for flow
cytometric (A), RT-PCR (B) and western blot (C)
analyses. Data in A and B were quantified using
Modfit and TotalLab software, respectively. 
(A) After U0126 treatment, slower progression
through G2/M was revealed by the delayed re-entry
of cells into the subsequent G1 phase. (B) RT-PCR
analysis indicated that U0126 treatment attenuated
the increase in cyclin B1 mRNA levels associated
with cell cycle progression through G2/M. GAPDH
mRNA levels were analyzed in parallel as loading
control. (C) Cell lysates were immunoblotted with
anti-ERK, anti-phosphoERK, anti-cyclin B1, anti-
Cdc25B and anti-tubulin antibodies. U0126
suppressed the phosphorylation of ERK, and the
expression of cyclin B1 and Cdc25B, but had no
effect on the expression of ERK and tubulin.
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FOXM1 in vivo. The enhancement of cyclin B1 promoter
activity by caMEK1 requires coexpression of functional
FOXM1, supporting the idea that the enhancing effect is
mediated through FOXM1. Unexpectedly, caMEK1 exerts an
enhancing effect on FOXM1c but not FOXM1b. It has
previously been demonstrated using semi-quantitative RT-PCR,
that FOXM1b is the major isoform expressed in skin whereas
FOXM1c is abundantly expressed in a variety of primary and
secondary cultured cell lines (Teh et al., 2002). Similar RT-PCR
analysis conducted in this study reveals FOXM1c as the
predominant isoform expressed in BJ1, NIH3T3 and several
tissues rich in mitotically active cells. High levels of the
FOXM1b transcript are only detectable in testis.
Sequence analysis identifies two ERK1/2 target sites
(PGS331P and PGS704P; Fig. 7A) that are conserved among the
human, mouse and rat FOXM1 proteins. Site-directed
mutagenesis and transient reporter assays demonstrate that both
the 331 and 704 motifs are of regulatory significance. Increased
phosphorylation of FOXM1 at serine residues upon ATA
treatment is also consistent with FOXM1 being a direct target of
Raf/MEK/MAPK signaling. The 331 motif is located within
exon Va. The difference in responsiveness of the two FOXM1
isoforms to caMEK1 enhancement pinpoints exon Va
(containing 15 amino acids), which is missing in FOXM1c, as
the regulatory site. The close proximity of exon Va to a putative
bipartite nuclear localization signal (NLS; Fig. S2 in
supplementary material) identified within exon VI suggests that
phosphorylation at exon Va may be relevant to regulation of
FOXM1 nuclear entry. It is interesting to note that the 704 motif,
localized within the transactivation domain, is close to the
cyclin-Cdk recruitment and Cdk1/2 phosphorylation sites
recently shown to be important for recruitment of p300/CBP
coactivators (Fig. 7A) (Major et al., 2004).
Consistent with our hypothesis that the Raf/MEK/MAPK
pathway mediates its G2/M regulatory effect via activation of
FOXM1 function, inhibition of Raf/MEK/MAPK signaling at S
and G2/M phases suppresses the G2/M-stimulated expression of
cyclin B1 at both RNA and protein levels. The dramatic
reduction in protein levels associated with the milder decrease
in transcript levels suggests active regulation of cyclin B1 by
protein degradation. Interestingly, decreased expression of
another putative FOXM1 target Cdc25B also precedes the G2/M
delay revealed by monitoring of G1 re-entry.
Based on these findings, we propose a model to depict
regulation of FOXM1 function by the Raf/MEK/MAPK
pathway and Cdk1/2 (Major et al., 2004) and hence cell cycle
progression through G2/M (Fig. 7B). FOXM1c is mainly
localized in the cytoplasm in S phase. Activation of the
Raf/MEK/MAPK pathway in late S phase leads to
phosphorylation of FOXM1c at the ERK1/2 sites. This
phosphorylation stimulates the nuclear import and
transactivating activity of FOXM1c. In the presence of active
cyclin-Cdk2 complexes (cyclin E/A-Cdk2), FOXM1c becomes
phosphorylated at the C-terminal Cdk1/2 sites and recruits
p300/CBP for transcriptional activation of target genes like
cyclin B1 and Cdc25B. Elevated cyclin B1 levels generate more
cyclin B1-Cdk1 complexes. These complexes become activated
by Cdc25B, which also accumulates and activates Cdk1 by
dephosphorylation. The heightened Cdk1 activity will further
phosphorylate and activate FOXM1c in a positive-feedback
loop, resulting in a burst of synthesis of active cyclin B1-Cdk1
to drive the cell into mitosis. This mode of regulation has a
switch-like property similar to other inputs previously shown to
regulate Cdk1 activity (O’Farrell, 2001) and is a very interesting
parallel to the transcriptional regulation of the ‘CLB2’ cluster of
genes (also peaking at G2/M) by the forkhead transcription
factors Fkh1 and Fkh2 in yeast (Kumar et al., 2000; Pic et al.,
2000; Zhu et al., 2000).
In summary, we demonstrate that nucleocytoplasmic shuttling
of FOXM1 is regulated in a cell cycle-dependent manner;
FOXM1 is translocated to the nucleus just before G2 phase.
Activation of the Raf/MEK/MAPK pathway is required for
promoting the nuclear entry and transactivating activity of
FOXM1. Expression of FOXM1 target genes and G2/M
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Fig. 7. A model to illustrate the cell cycle-dependent regulation of FOXM1c function. (A) Location of the PGS331P and PGS704P ERK1/2
phosphorylation sites (shown in red circles). The 331 motif within exon Va (yellow) is close to the DNA binding domain (DBD, red) and a
putative NLS (sequence of the NLS is provided in Fig. S2 of the supplementary material). The 704 motif is in close proximity to the Cdk
phosphorylation sites (green circles) identified within the transactivating domain (TAD, violet). (B) During late S phase, the Raf/MEK/MAPK
pathway phosphorylates FOXM1 and stimulates its nuclear translocation and transactivating activity. Active cyclin-Cdk2 (Cyclin E/A-Cdk2)
phosphorylates FOXM1 at the Cdk1/2 phosphorylation sites within the TAD. This promotes recruitment of p300/CBP and transcription of
FOXM1 target genes like cyclin B1 and Cdc25B. Cdk1 becomes activated by binding of cyclin B1 and dephosphorylation by Cdc25B. Active
cyclin B1-Cdk1 phosphorylates FOXM1 and further promotes transcription of cyclin B1 and Cdc25B. This positive-feedback loop produces a
burst of cyclin B1-Cdk1 activity to drive the cell into mitosis.
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progression is suppressed when Raf/MEK/MAPK signaling is
inhibited. Our data provide the first evidence to support a
functional link between Raf/MEK/MAPK signaling and
FOXM1 in the regulation of cell cycle progression through
G2/M.
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